Imagine being a pharmaceutical startup or an in-house counsel at a mid-sized pharma company in India. You’re preparing to launch a generic version of a life-saving drug. Suddenly, you get a cease-and-desist letter from a multinational: “Stop sales immediately, or we’ll sue you for patent infringement.” Your heart races, and your mind goes into overdrive. This is exactly what happened in Merck Sharp & Dohme (MSD) v. Glenmark Pharmaceuticals, a landmark case that changed how Indian courts look at injunctions in pharmaceutical patent disputes.
If you’re navigating patents, generics, or just trying to understand how public interest shapes litigation in India, this case is a must-know. Let’s break it down, step by step, in plain language.
Why Merck v. Glenmark matters
Back in 2014–2015, MSD held an Indian patent covering Sitagliptin, a drug used to treat type 2 diabetes. Glenmark Pharmaceuticals, a domestic company, wanted to launch a generic version. MSD responded with a legal suit seeking an interim injunction to stop Glenmark from selling its product.
Here’s the twist: the Delhi High Court had to consider not just patent validity, but also public health implications. India’s courts had already shown in cases like Bayer v. Natco and Novartis v. Union of India that public interest cannot be ignored, especially for essential medicines. MSD v. Glenmark tested how far this principle would extend in injunction applications.
The legal framework: what Indian law says
Let’s keep it simple. When a patentee claims infringement, these are the key statutory touchpoints:
Section 48, Patents Act, 1970 - Grants patentees exclusive rights over their invention. Basically, no one can make, use, sell, or distribute your patented product without permission.
Section 104, Patents Act, 1970 - Empowers courts to grant interim or permanent injunctions in infringement cases.
Specific Relief Act, 1963 (Order XXXIX) - Outlines the three-pronged test for temporary injunctions:
Prima facie case
Irreparable injury
Balance of convenience
In India, courts also consider public interest, particularly when a drug is essential for patients who might otherwise be denied treatment.
Case background: MSD vs Glenmark
Here’s the story in a nutshell:
MSD owned Indian Patent No. 209816, covering Sitagliptin and its salts.
Glenmark sought to launch its generic version under the brand name Zita and Zita-Met.
MSD claimed that Glenmark’s products infringed its patent and approached the Delhi High Court for an interim injunction.
This case wasn’t just about dollars and cents. It was about patient access, affordability, and the role of courts in balancing innovation with public health.
Court proceedings and analysis
Single Judge’s decision
Initially, a Single Judge at the Delhi High Court denied MSD’s application for an interim injunction. Why? The court applied the traditional three-pronged test but emphasized that patent rights are not absolute. In particular, it considered:
The potential public harm if the generic was blocked
Evidence presented on the actual market impact and availability of alternatives
The court concluded that MSD had not demonstrated irreparable harm sufficient to justify an immediate injunction.
Division Bench reversal
MSD appealed, and a Division Bench reversed the Single Judge’s decision. The bench carefully evaluated:
Prima facie case – The court found that MSD had a valid patent and that Glenmark’s products fell within the scope of the patent claims.
Irreparable harm – MSD demonstrated that it could suffer significant market and reputational harm if the generic launched.
Balance of convenience – While public interest was important, the bench held that MSD’s proprietary rights needed protection until full trial evidence could be heard.
This decision highlighted the tightrope courts walk in pharma patent injunctions—protecting patent holders while considering the broader public interest.
Supreme Court’s stay
Glenmark then approached the Supreme Court, which issued a limited stay. This move underlined that interim injunctions in pharma cases are not cut-and-dried; each stage can shift the balance, depending on evidence presented and public health considerations.
Jurisprudential insights
Several key lessons emerge from this case:
1. Patent claim construction matters
The dispute hinged on how the court interpreted MSD’s patent claims. Specifically:
Was Sitagliptin itself covered, or only certain salts?
Did Glenmark’s product fall within the claim scope?
The court’s detailed analysis showed that even minor differences in chemical composition can determine whether infringement is established. This is a crucial point for patent drafting and enforcement.
2. Public interest is a real factor
Indian courts don’t grant injunctions automatically, especially for essential medicines. Judges explicitly weighed:
Number of patients affected
Price difference between branded and generic drugs
Availability of alternative treatments
The takeaway: public health can override commercial interests, at least temporarily, until a full trial is completed.
3. Procedural nuances influence outcomes
The journey from the Single Judge to the Division Bench and eventually to the Supreme Court shows that:
Interim relief is not permanent; it can shift as evidence emerges
Strategic filing and evidence presentation can make or break the case
Courts expect detailed, credible, and timely documentation from both sides
Comparative analysis: how this fits in the bigger picture
Bayer v. Natco
India’s first compulsory license case.
The court allowed Natco to produce a generic for Bayer’s Nexavar due to affordability and public interest.
Demonstrates that injunctions and enforcement are not absolute in Indian pharma law.
Novartis v. Union of India
Focused on patentability under Section 3(d) for Glivec.
While not an injunction case, it set the tone for how incremental modifications are scrutinized in India.
Together with MSD v. Glenmark, these cases form a trilogy showing Indian courts’ nuanced approach to balancing innovation, public health, and patent rights.
Practical implications for stakeholders
For patent holders
Draft strong claims and maintain a robust patent prosecution history.
Document R&D and commercial plans to demonstrate irreparable harm in court.
Prepare public-interest rebuttals - affordability programs, compassionate use initiatives, and distribution data help.
For generic manufacturers
Collect market data and patient-impact evidence before launching.
Prepare public-interest affidavits to support your defense.
Analyze patent claims carefully to avoid inadvertent infringement.
For policymakers
Consider affordability, patient access, and public health in IP regulations.
Encourage transparent licensing frameworks to balance innovation with social needs.
Key takeaways
No automatic injunctions: Indian courts evaluate evidence and public health impact.
Evidence is everything: Technical reports, sales data, and regulatory approvals carry weight.
Public interest can tip the scale: Access to essential medicines is prioritized, at least temporarily.
Procedural strategy matters: From Single Judge to Division Bench, each step requires meticulous preparation.
FAQs
Q1: Does every pharma patent automatically get an injunction in India?
No. Courts consider prima facie validity, irreparable harm, balance of convenience, and public interest.
Q2: Can a generic launch be blocked immediately?
Only if the court is convinced that the patentee meets the three-pronged injunction test.
Q3: How long do interim injunction hearings usually take?
A few weeks to months, depending on the court and complexity of evidence.
Q4: What if regulatory approval for the generic is pending?
Courts examine whether approval is likely soon; pending approvals may influence the balance of convenience.
Q5: How much does litigation cost?
Varies widely; multi-expert, multi-court proceedings can cost tens of lakhs, sometimes more.
Q6: Should companies seek regulatory clearance before approaching the court?
Yes, parallel preparation strengthens the case and demonstrates readiness to comply with legal and safety standards.
Closing thought
Merck Sharp & Dohme v. Glenmark Pharmaceuticals is more than a patent dispute; it’s a blueprint for understanding how Indian courts handle injunctions in life-saving drug cases. It teaches us that evidence, claim construction, and public interest all matter - and that interim injunctions are far from automatic.
For founders, patent holders, or generic manufacturers, the lesson is clear: prepare early, document meticulously, and understand both legal and public health dimensions. The cost of underestimating any of these factors can be massive - financially, legally
